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responsibility of XAbstract A new simple, sensitive and precise green analytical procedure using an automated
packed-reactor derivatization technique coupled with on-line solid-phase enrichment (SPEn)
has been developed and evaluated to determine trace levels of methotrexate (MTX). The
method was based on injection of MTX into a ﬂowing stream of phosphate buffer (0.04 M, pH
3.4), carried through the packed oxidant reactor of Cerium (IV) trihydroxyhydroperoxide for
oxidative cleavage of the drug into highly ﬂuorescent product, 2,4-diaminopteridine-
6-carboxylic acid, followed by SPEn on a head of short ODS column (10 mm 4.6 mm
i.d., 5 mm particle size). The ﬂow rate was 0.25 mL/min and packed reactor temperature was
40 1C. The trapped product was back-ﬂush eluted from the ODS column to the detector by
column-switching with an environmentally friendly mobile phase consisting of ethanol and
phosphate buffer (0.04 M, pH 3.4) in the ratio of 5:95 (v/v). The eluent was monitored at
emission and excitation wavelengths of 460 and 360 nm, respectively. The calibration curve
was linear over the concentration range of 1.25–50 ng/mL with a detection limit of 0.08 ng/mL.ersity. Production and hosting by Elsevier B.V. All rights reserved.
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On-line coupling of derivatization with preconcentration to determine trace levels of methotrexate 29The method was successfully applied to determine MTX in pharmaceutical formulations with
mean percentage recovery ranging from 99.48 to 99.60.
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Methotrexate (MTX, 2,4-diamino-4-deoxy-N10-methylptero-
glutamic acid) is one of the most widely used antifolate
(Scheme 1) drugs that show signiﬁcant antitumor activity in
acute leukemia and other neoplastic diseases [1].
Many methods have been developed for the determination of
MTX, including spectroﬂuorimetry [2–4], immunoassay [5], capil-
lary electrophoresis [6,7] and high-performance liquid chromato-
graphy (HPLC) with UV detection [8–13]. Due to its higher
sensitivity and selectivity, the measurement of low MTX level was
more precise in the HPLC with ﬂuorescence detection [14–25].
MTX does not show native ﬂuorescence but it can be derivatized
into strongly ﬂuorescent product after variety of successful
analytical schemes. Several methodologies have been developed
for the derivatization of MTX into a highly ﬂuorescent product,
2,4-diaminopteridine-6-carboxylic acid. These methods were based
on photo-oxidative irradiation [14,20], electrochemical oxidation
[16,17], oxidation with permanganate [2,4,18,21,25] and hydrogen
peroxide [19,22–24]. The United State Pharmacopoeia for the
determination of MTX is based on HPLC with UV detection [26].
In recent years, more strict regulation related to the quality
control of pharmaceuticals led to increasing demands on
automation of the analytical assays carried out in appropriate
control laboratories. The ﬂow injection analysis (FIA) became
a versatile instrumental tool that contributed substantially to
the development of automation in pharmaceutical analysis due
to its simplicity, low cost and relatively short analysis time.
A survey of the literatures reveled that there are few methods
for FIA determination of MTX in pharmaceutical formula-
tions [27,28]. These methods were based on the oxidation of
MTX into highly ﬂuorescent product 2,4-diaminopteridine-6-
carboxylic acid by on-line electrochemical oxidation and
acidic potassium permanganate. A sequential injection analy-
sis has also been reported for the determination of MTX
using amperometric biosensor as detector [29]. Cerium (IV)Scheme 1. Structures of thetrihydroxyhydroperoxide (CTH) has been introduced as a
packed reactor in a ﬂowing system for conversion of MTX
into a highly ﬂuorescent product, 2,4-diaminopteridine-6-
carboxylic acid (Scheme 1) [30].
Determination of trace amount of drugs is an important issue
in quality control of pharmaceuticals. Appropriate selection of
pre-concentration methods for on-line sample processing and
suitable detection allows the development of FIA methods for
such analysis. Especially satisfactory for this purpose is the
application of a measuring system combining FIA with on-line
solid-phase enrichment (SPEn). In the present work, a single line
FIA packed reactor procedure combined with on-line SPEn was
developed to determine MTX. The method was based on
oxidative cleavage of MTX into highly ﬂuorescent product,
2,4-diaminopteridine-6-carboxylic acid, by means of CTH packed
oxidant. At the same time the ﬂuorescent product of MTX was
pre-concentrated on a suitable short ODS column before detec-
tion. This approach presented interesting features such as: (i) high
selectivity; (ii) high sensitivity; (iii) rapidity, simplicity and low cost,
compared to well established FIA methods. In addition, packed
reactor FIA used for the oxidative cleavage of MTX avoids the
use of chemical reagents, which frequently are expensive and/or
harmful; it is therefore an environmentally friendly analytical
method. Moreover, the implementation of FIA-SPEn is a very
attractive and fruitful research ﬁeld, since this approach is
appropriated as automated pre-concentration method, in order
to determine MTX at trace levels (0.27 ng/mL). The proposed
method was fully validated and proved to be adequate for
quantiﬁcation of MTX in pharmaceutical formulations.
2. Experimental
2.1. Instrumentation
A single line FIA-SPEn manifold, illustrated in Fig. 1, con-
sisted of two solvent delivery pumps (Agilent 1100 Series Isoinvestigated compounds.
Waste 
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Fig. 1 Schematic diagram of on-line-SPEn coupled to packed
reactor FIA for the trace analysis of MTX in pharmaceutical
formulations. (A) Shows the system in initial position, ready for
sample injection, derivatization and enrichment steps. (B) Dis-
plays the back-ﬂush elution and detection step. SV, 6-port
switching valve.
S. Emara et al.30pump G1310A); one used to deliver the carrier solution at a
ﬂow rate of 0.25 mL/min and the other to deliver isocratic
mobile phase at a ﬂow rate of 1 mL/min. This system was
equipped with two columns; one was a short (70 mm 4.6 mm
i.d.) CTH packed oxidant column for oxidative-cleavage of
MTX into highly ﬂuorescent product and the other was a
small TSK gel ODS-80 TM column (10 mm 4.6 mm i.d.,
5 mm particle size) for pre-concentration of the ﬂuorescent
product. A model 7125 sample injection valve (400 mL) and a
model 7010 ﬂow direction switching valve were applied to load
the sample onto the CTH packed oxidant and facilitate
oxidative cleavage of MTX into highly ﬂuorescent product
and to elute the enriched analyte in a back-ﬂush elution mode
to the detector, (Rheodyne, Berkeley, CA, USA) respectively.
A ﬂuorescence detector (Agilent 1200 series, G1321A) mon-
itored the eluent, set at an excitation wavelength of 360 nm
and an emission wavelength of 460 nm. Data acquisition was
performed on an Agilent LC ChemStation software. The ODS
column temperature was ambient, while that of the CTH
packed reactor was 40 1C.
2.2. Reagents and chemicals
MTX (99.83%) was obtained from Kyowa Hakki (Tokyo,
Japan). The present method was applied to the determination
of MTX in its pharmaceutical formulations: (1) Methotrexate
tablets (Batch No. 1368454) 2.5 mg of MTX and (2) Metho-
trexate vials (Batch No. 1236627) 50 mg of MTX (Orion
Corporation, Finland). Ethanol used was HPLC grade (BDH,
Poole, UK). Distilled water was used for the preparation of all
reagents and solutions. Potassium dihydrogen phosphate,
ortho-phosphoric, chloroform and isopropyl alcohol used
were of analytical grades. TSK gel ODS-80 TM silica (5 mm)
was from Tosoh Corporation (Tokyo, Japan).
2.3. Standard solutions
Stock standard solution of MTX (100 mg/mL) was prepared
by dissolving an accurately weighed amount of MTX (25 mg)
in 250 mL of distilled water. A known volume of the stock
standard solution was diluted with the same solvent to obtaina concentration of 1 mg/mL MTX (solution A). The standard
solutions for calibration were prepared daily by serial dilutions
of appropriate volumes of solution A to produce MTX
standard solutions in the ﬁnal concentration range of 1.25–
50 ng/mL. An aliquot of 400 mL was analyzed for MTX
according to the proposed procedure. The standard solutions
were stored frozen at 20 1C until used.
2.4. Tablets
A total of 20 tablets containing MTX as the active ingredient
were weighed and ﬁnally powdered. A portion of the powder
equivalent to 25 mg of MTX was accurately weighed and
transferred to a 250 mL calibrated ﬂask and dissolved in
about 200 mL of distilled water using an ultra sonic bath.
The solution was diluted to the volume with the same solvent
and then ﬁltered. The ﬁrst portion of the ﬁltrate was discarded
and the remainder was used as a stock sample solution
(solution A, 0.1 mg/mL). A known volume of solution
A was diluted quantitatively with distilled water to obtain a
concentration of 1 mg/mL MTX (solution B). A further
dilution was carried out to obtain a ﬁnal concentration of
20 ng/mL MTX. An aliquot of 400 mL was analyzed for MTX
according to the proposed procedure.
2.5. Vials
An accurately volume equivalent to 25 mg MTX was trans-
ferred to a 250 mL calibrated ﬂask and completed to the mark
with distilled water. Serial dilutions as described under
analysis of tablets were made to obtain a ﬁnal concentration
of 20 ng/mL. An aliquot of 400 mL was analyzed for MTX
according to the proposed procedure.
2.6. Mobile phases
Two different mobile phases were employed in the assay
procedure. One was phosphate buffer (0.04 M, pH 3.4) (MI),
which was used to deliver sample to the CTH packed oxidant
in the oxidation step. The other was an isocratic solvent
system (MII) consisting of ethanol and phosphate buffer
(0.04 M, pH 3.4) (5:95 v/v) which was used to elute the
enriched ﬂuorescent product in a back-ﬂushed mode from
the head of the small ODS column to the ﬂuorescence
detector. All mobile phases were freshly prepared on the day
of use, ﬁltered through 0.45 mm ﬁlters (Millipore, Billerica,
MA), and degassed ultrasonically under vacuum.
2.7. Preparation of ODS and CTH columns
The ODS (TSK gel ODS-80 TM, 5 mm particle size) and CTH
packing materials were suspended in chloroform and isopro-
pyl alcohol, respectively. The suspended materials were
degassed under vacuum with continuous stirring for 10 min.
A stainless-steel cylinder (100 mm 4.6 mm i.d.) was used as a
reservoir for the packing materials. This reservoir was con-
nected to a short column (10 mm 4.6 mm i.d.) for ODS
materials and another column (70 mm 4.6 mm i.d.) for CTH
oxidant. The suspended ODS and CTH supplied from the
reservoir were packed into the corresponding columns with the
aid of an HPLC pump at a ﬂow-rate of 5 mL/min with ethanol
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Fig. 2 Effect of phosphate buffer pH on the reaction efﬁciency of
CTH packed reactor with MTX.
On-line coupling of derivatization with preconcentration to determine trace levels of methotrexate 31as a purge solvent (10 min). Pumping must continue until a
constant pressure is reached. The cylinder was then discon-
nected and a mixture of ethanol and distilled water (1:1) was
passed through the columns at a ﬂow rate of 1 mL/min for
further 10 min. The columns were then equilibrated with
phosphate buffer (0.04 M, pH 3.4) at a ﬂow rate of 1 mL/
min for 30 min.
2.8. General procedure
A 400 mL aliquot of MTX sample was loaded into the injection
valve and then injected into MI (position A, Fig. 1). The moving
zone of MTX passed through the CTH packed reactor at a ﬂow
rate of 0.25 mL/min (pump I). The oxidative cleavage of MTX
occurs during the ﬂow of MI containing the drug through the
CTH column. Pre-concentration was performed by means of the
ﬂow of the ﬂuorescent product from the packed oxidant column
to the short ODS column head. After 4 min the switching valve
was switched into position B (Fig. 1). At this position, the MII
could pass through the ODS column, where the ﬂuorescent
product was eluted in a back-ﬂush mode to the detector.
The ﬂow rate was maintained at 1 mL/min and the ﬂuorescence
intensity of the eluting compound was monitored at emission and
excitation wavelengths of 460 and 360 nm, respectively. At 5 min
after injection, the switching valve was switched into position A to
be ready for the next injection.3. Results and discussion
The use of a packed reactor, in the described FIA-SPEn assembly,
as an alternative to existing reagent solutions for the determination
of MTX is dependent on optimization of the system to achieve
maximum detector response. On the basis of experimental results,
it can be stated that pH, concentration and ﬂow rate of carrier
stream as well as packed reactor temperature are the key
parameters to improve derivatization step (position A, Fig. 1).
The other parameters optimized were: pH and buffer concentra-
tion as well as the concentration of ethanol used as organic
modiﬁer in the elution step (position B, Fig. 1).
3.1. Effect of pH and concentration of carrier stream
Carrier stream pH is a very important chemical parameter that
has to be investigated. The correct adjustment of this variable
is necessary to improve the reaction completeness between the
analyte and CTH packed reactor. The inﬂuence of this
parameter on the analytical signal was studied in the pH
range of 2.8–5 using buffer solutions from phosphate and
acetate. Phosphate buffer gave the best performance as a
carrier stream and was selected in all further experiments. The
analytical signal reached its maximum value in the narrow
range of pH 3.2–3.6 (Fig. 2). At pHo3.0, a low signal
response was observed which might suggest the decomposition
of the peroxy groups of the CTH materials, whereas at
pH43.8, the detector signals were decreased abruptly prob-
ably due to the low CTH reactor efﬁciency which reduces
drastically the oxidative cleavage of MTX into highly ﬂuor-
escent derivative. Accordingly, phosphate buffer solution of
pH 3.4 was selected as the optimum carrier stream.
To ﬁnd out the suitable salt concentration, phosphate
buffers of concentrations varying from 0.02 to 0.1 M wereexamined at the optimum pH. Best analytical signals were
veriﬁed within the concentration range of 0.02–0.05 M
(Fig. 3). Above this range, the peak area that corresponds to
the analyte was signiﬁcantly decreased probably due to greater
quenching effect on the ﬂuorescence signal intensity.
Although, 0.02 M phosphate buffer showed slight improve-
ment of signal intensity, 0.04 M was chosen as a compromise
between detector response and precision.
3.2. Effect of ﬂow rate
The contact time (residence time) between the sample zone
containing MTX and the solid-phase reactor is very important
for the reaction to proceed sufﬁciently and to achieve a
substantial enhancement of the detector response. As the
residence time depends on the ﬂow rate of the carrier stream
through the CTH packed reactor, a study of the ﬂow rate was
examined over the range of 0.25–2 mL/min (at 0.25 mL/min
interval). The results showed an increase in the peak area at the
lower ﬂow rate down to 0.25 mL/min. It could be postulated that
any decrease in the ﬂow rate will increase the residence time
between the moving zone of MTX and solid surface of CTH
reactor, because of the increased diffusion of a sample zone over
a larger area. The negative effect of the use of increasing ﬂow
rate on the reaction yield of MTX with CTH was also observed.
Unlike previously reported assay using the conventional packed
reactor FIA approach [30], a lower ﬂow rate was justiﬁed in the
present work for the determination of MTX because peak
enrichment could be achieved on the top of the small ODS
column. As far as the oxidation reaction proceeded, 2,4-diami-
nopteridine-6-carboxylic acid could be accumulated on the top of
the ODS column with a zone width almost independent on the
ﬂow rate. A carrier ﬂow rate of 0.25 mL/min was effective for the
proposed FIA-SPEn method, achieving detection limit of
0.08 ng/mL for a sample size of 400 mL.
3.3. Effect of temperature
The oxidative cleavage of MTX into highly ﬂuorescent
product with CTH could be performed at room temperature
while the highest detector response was achieved at elevated
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Fig. 4 Effect of temperature on the reaction efﬁciency of CTH packed reactor with MTX.
S. Emara et al.32temperature. At the same time, experimental results showed a
generally drastic effect of temperature on the CTH packed
oxidant life span. Accordingly, the effect of temperature on
the ﬂuorescent intensity of MTX was investigated in the range
of 25–65 1C by thermostating the packed oxidant reactor. It
was found that if the reaction temperature was too low, the
time of reaction needed was too long, and the oxidative
cleavage could not be completed, while elevating the tempera-
ture within the range of 25–65 1C resulted in an increase in the
reaction rate and peak area (Fig. 4). Owing to the packed
oxidant limitations, 40 1C was chosen as the optimum value
because under this condition, good sensitivity and reproduci-
bility were achieved.
As a result, the optimal oxidation reaction efﬁciency of the
CTH packed reactor could be achieved by using phosphate
buffer (0.04 M, pH 3.4) at a ﬂow rate of 0.25 mL/min and
reactor temperature of 40 1C.3.4. Sample volume
In an effort to push the concentration detection limit to a lower
level, we attempted to use an on-line SPEn technique to pre-
concentrate the ﬂuorescent product before detection by loading
a large sample volume of MTX. The design of a switching valve
containing a small ODS column for on-line sample enrichment
was described (Fig. 1, position A). Samples were loaded onto
the CTH packed oxidant with a carrier mobile phase (MI) and
pump I, while pre-concentration was performed by means of
ﬂowing of the ﬂuorescent product from the packed reactor to
the ODS column head. Different injection volumes (50–500 mL)
were tested to introduce decreasing concentration of MTX. The
efﬁciency of enrichment for ﬂuorescent product was evaluated
on the basis of the linearity of calibration curve constructed
over sample volumes (50–400 mL, at 50 mL interval). It was
found that, the CTH packed oxidant could tolerate large
Table 1 Characteristic parameters for the regression
equations of the proposed FIA method.
Parameters MTX
Calibration range (ng/mL) 1.25–50
Detection limit (ng/mL) 0.08
Quantitation limit (ng/mL) 0.27
Slope (b) 1.4286
Standard error of the slope 0.0090
Intercept (a) 0.3030
On-line coupling of derivatization with preconcentration to determine trace levels of methotrexate 33volumes of MTX standard solution and the linear relationship
(r2 0.9995) between the peak area and the injected volumes was
observed over the range of 50–400 mL sample volume. If too
large sample volume is used (more than 400 mL), then the
linearity of MTX between the peak area and concentration will
be disturbed because a long residence time was found to be
necessary to get reproducible results upon using large volume of
MTX samples. Accordingly, sample volume of 400 mL MTX
sample was selected as a compromise between the sensitivity
and accuracy.Standard error of the intercept 0.2222
Correlation coefﬁcient (r2) 0.9997
Y¼aþbC, where C is the concentration of MTX in ng/mL and
Y is the peak area.3.5. Breakthrough study of ODS small column
A small reversed-phase column was inserted in a switching
valve between the solid CTH packed reactor and ﬂuorescence
detector as schematically shown in Fig. 1 (position A).
For optimal on-line pre-concentration conditions, with respect
to band broadening, the retention of the ﬂuorescent product
should be high at enrichment mode and low at elution mode,
i.e., the reversed-phase column hydrophobicity should be as
high as possible for complete trapping of the ﬂuorescent
product for enrichment. In the current study, TSK gel ODS-
80 TM silica was chosen to be suitable packing material for
the preparation of easily replaceable short column. A break-
through study was performed by injecting 400 mL sample
containing MTX (20 ng/mL) onto the ODS column, by means
of MI. Increasing volume of MI was pumped through the
column, before the switching valve was switched to position B
(Fig. 1) and the trapped product was brought to the ﬂuores-
cence detector with the analytical mobile phase (MII). With up
to 10 mL of phosphate buffer (0.04 M, pH 3.4), pumped
through the ODS column, the recovery of the analyte was
above 99%. These results indicated complete trapping of
MTX on the ODS column during the enrichment step.3.6. Optimization of the back-ﬂush elution step
Once the derivatization and enrichment step was terminated,
the switching valve was switched to position B (Fig. 1) and the
ﬂuorescent product was transferred to the detector in a back-
ﬂush mode with MII. Thus, the time needed to elute the
product from the ODS column and to transfer it to the
detector with MII was then tested. The optimization proce-
dure was continued by changing pH of the analytical mobile
phase (MII) as well as changing the ratios of ethanol and
phosphate buffer. Variation in the pH in the range of 2.0–6
weakly affected retention behavior of the ﬂuorescent product.
Variation of ethanol concentration was found to strongly
affect retention behavior and band broadening of the ﬂuor-
escent product. As a result, the optimal elution efﬁciency of
the analytical mobile phase (MII) could be achieved by using a
green solvent system of ethanol and phosphate buffer (0.04 M,
pH 3.4) in the ratio 5:95 (v/v). Due to the elution strength of
MII, a time period of less than 1 min was sufﬁcient to perform
complete elution of the ﬂuorescent product from the head of
ODS column (10 mm 4.6 mm i.d.). By this means, much
faster analysis was possible and the productivity of proposed
FIA-SPEn method could be increased.3.7. Method validation
3.7.1. Linearity
The calibration curve for MTX was constructed with seven
concentrations (simultaneously prepared) ranging from 1.25 to
50 ng/mL. Calibration curve was constructed by plotting the
measured peak area of 2,4-diaminopteridine-6-carboxylic acid
versus concentration. Each concentration was repeated three
times; this approach provided information on the variation in
peak area values between samples of same concentration.
The linearity of the calibration curve was validated by the high
value of the correlation coefﬁcient (0.9997). The coefﬁcient for
the linear equation Y¼aþbC was calculated using the linear
regression least squares method, where Y is the peak area and
C denotes the concentration in ng/mL of the tested compound.
Characteristic parameters of the linear calibration curve are
shown in Table 1.
3.7.2. Limits of detection and quantiﬁcation
The limit of detection (LOD), deﬁned as the lowest concen-
tration of MTX that can be clearly detected above the base
line signal, is estimated as three-times the signal-to-noise ratio.
The LOD was determined (n¼3) by injection of MTX in
decreasing concentrations. The LOD was found to be 0.08 ng/
mL (Table 1). The limit of quantiﬁcation (LOQ) is often
deﬁned as 10 times the signal-to-noise ratio. The LOQ was
determined (n¼3) by injection of MTX in decreasing concen-
trations. The precision was calculated for each concentration.
Then, the LOQ was calculated as the concentration, where the
precision was less than or equal to 15% and was found to be
0.27 ng/mL (Table 1).
3.7.3. Precision and accuracy
The relative standard deviation (RSD %) and the relative error
(RE %) of the mean measured concentration were served as
measures of accuracy and precision for validation of the assay
procedure. The intra- and inter-day assay precision and accu-
racy for MTX are summarized in Table 2. Within the examined
range, the intra-day reproducibility and accuracy of the assay
were excellent, with RSD % being in the range of 0.09–0.28 and
with RE % ranging from 0.26 to 0.54. The inter-day RSD %
were 0.11–0.32 and the mean RE % ranged from 0.34 to 0.65.
Repeatability and reproducibility of MTX samples with high
and low concentration levels were below 0.70%, indicating a
reliable measurement using the proposed method (Table 2). RE
Table 2 Precision and accuracy validation of MTX.
Concentration
(ng/mL)
Intra-assaya Inter-assaya
Mean
recovery
(%)a7RSD
Mean
RE
(%)
Mean
recovery
(%)a7RSD
Mean
RE
(%)
5 99.6270.09 0.38 99.4870.11 0.52
10 99.7470.17 0.26 99.6670.19 0.34
20 99.6570.23 0.35 99.6070.27 0.40
40 99.4670.28 0.54 99.3570.32 0.65
aAverage of ﬁve determinations.
Table 3 Determination of MTX in commercial formula-
tions by the proposed and ofﬁcial methods.
Commercial
formulation
Recovery (%) a7RSD
Proposed
method
Ofﬁcial
method
Tablets (20 ng/mL) 99.5670.26 99.7770.21
Student’s t-test 0.28 (2.30)b
F-test 1.57 (6.38)b
Vials (20 ng/mL) 99.6870.23 99.8770.20
Student’s t-test 0.27 (2.30)b
F-test 1.37 (6.38)b
aAverage of ﬁve determinations.
bTheoretical values at p¼0.05.
S. Emara et al.34was evaluated by back-calculation and expressed as the percent
deviation between concentration added and concentration found
according to the following:
RE%¼ ½ conc: added 2 conc: foundð Þ=conc: added  100%
3.7.4. Interference studies
In order to examine the selectivity of the proposed method, the
effect of common excipients normally used in pharmaceutical
formulations was studied. Solutions containing MTX (20 ng/mL)
in the presence of more than 100-folds of common additives such
as maize starch, calcium hydrogen phosphate, magnesium stea-
rate, mannitol, red ferric oxide, lactose, methylhydroxypropylcel-
lulose, sodium stearyl fumarate, microcrystalline cellulose, hydr-
ophobic colloidal silica and sucrose were prepared. The undis-
solved materials were ﬁltered off before injection. No signiﬁcant
changes were observed on the results and recoveries in the range of
99.38–99.61% were obtained in all cases.
3.8. Application
The proposed FIA-SPEn method was applied for the determina-
tion of MTX in its commercial formulations together with the
ofﬁcial USP method [26]. As indicated, the assay results, of
pharmaceutical formulations, obtained by the proposed method
were in accordance with those obtained by the ofﬁcial USP
method (Table 3). The accuracy and precision of the developed
method were further judged by applying t- and F-test at 95%
conﬁdence level. The experimental t- and F- values did not exceed
the theoretical values, which support the similar accuracy and
precision of the proposed and ofﬁcial USP methods (Table 3).
The accuracy of the analytical method was also checked by
standard addition method, which is applied by adding drug
standard to previously analyzed tablets. The results showed that
the derivatization procedure developed for the determination of
MTX could be considered to be accurate within the concentration
range investigated. Mean value is very close to the theoretical
concentration, showing percentage recovery of 99.48 and 99.60
and RSD of 0.31 and 0.28 for MTX tablets and vials, respectively.
These results indicate that the effects of the common additives and
ingredients of the pharmaceutical formulations do not interfere
with the determination of MTX.
High reagent consumption is the main disadvantage of all
continuous FIA systems, which use the reagent continuously even
when no sample is present in the apparatus [27–29,31]. In the
present work, the packed reactor of CTH avoids this unecono-
mical approach in such a way that the sample zone meets thereactor in a controlled manner while the rest of the system is ﬁlled
with phosphate buffer (0.04 M, pH 3.4). Also, the use of CTH
reactor offers many signiﬁcant improvements over the other FIA
procedures for the determination of MTX. These improvements
are simpliﬁcation of manifold, saving reagents, no mixing pro-
blems, less pump noise and the reaction is very mild and the
derivatization is achieved in a fairly short time. The use of
phosphate buffer (0.04 M, pH 3.4) as a ﬂowing stream and a
mobile phase consisting of ethanol and phosphate buffer (0.04M,
pH 3.4) in the ratio of 5:95 (v/v) made this work as a contribution
to environmentally friendly analytical chemistry. Moreover, the
implementation of FIA-SPEn is a very attractive and fruitful
research ﬁeld, since this approach can achieve an improvement of
sensitivity of around a 20-fold compared with the reported FIA
method using CTH packed reactor [30].
3.9. Robustness
To determine robustness of the proposed method, experimen-
tal conditions, namely ﬂow rate, pH and concentration of the
buffer solution used as a carrier stream, packed reactor
temperature and organic content of the mobile phase were
purposely altered and the detector responses were evaluated.
Variation of each parameter by 72% did not have a
signiﬁcant effect on the detector response.4. Conclusion
The present study has demonstrated that MTX could be
determined using an automated green analytical procedure
based on the formation of ﬂuorescent product, 2,4-diaminop-
teridine-6-carboxylic acid, on a CTH packed oxidant coupled
with on-line SPEn on the head of a small ODS column for pre-
concentration before detection. The use of solid-phase reactor
incorporated into the FIA manifold offers many signiﬁcant
improvements over the other FIA procedures for the determi-
nation of MTX. These improvements are simplicity of the
procedure, no dangerous reagents used, very mild reaction
conditions, no mixing problems and less pump noise. A high
robustness degree of on-line derivatization-SPEn strategy,
good reproducibility, and simplicity demonstrates the suit-
ability of the method for routine analysis and quality control
On-line coupling of derivatization with preconcentration to determine trace levels of methotrexate 35of MTX in pharmaceutical formulations. Common excipients
used as additives in pharmaceutical preparations did not
interfere.
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